Kestra Medical Technologies, Lt
KMTS
Positions held
Your positionsKMTS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Kestra Medical Technologies is positioned in a growing healthcare sector, focusing on innovative medical instruments that can enhance patient care and operational efficiency.
- The company reported a revenue increase of 8% compared to the prior quarter, reaching $31 million.
- Gross margin improved to 56.5%, up from 54.8% in the previous quarter.
- Despite the revenue growth, Kestra has a negative profit margin of -1.4%, indicating ongoing financial challenges.
- The operating margin remains significantly negative at -121.6%, reflecting high operational costs.
- The company has a forward P/E ratio of -13.19, suggesting that investors are cautious about future earnings potential.
Fundamentals
| Market cap | $1.53B | Enterprise value | $1.41B | Trailing P/E | — | Forward P/E | -12.54 |
| PEG | — | Price / book | 6.87 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 59.9% | Earnings growth | — | Gross margin | 53.9% | Operating margin | -121.6% |
| Profit margin | -140.4% | ROE | -73.7% | ROA | -29.2% | Debt / equity | 0.34 |
| Current ratio | 4.69 | Free cash flow | -$72.03M | Analyst recommendation | strong_buy | Mean target | $30.29 |
| 52w high | $30.00 | 52w low | $17.34 |
Quarterly
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|---|
| Revenue | $31.0M | $28.6M | $24.6M | $22.6M | $19.4M | — |
| Op margin | -121.6% | -137.4% | -141.6% | -140.7% | -149.1% | — |
| Net income | -$44.1M | -$38.8M | -$34.2M | -$32.8M | -$25.8M | — |
| Gross margin | 56.5% | 54.8% | 52.6% | 50.6% | 45.7% | — |
| Gross profit | $17.5M | $15.7M | $12.9M | $11.4M | $8.9M | — |
| Operating income | -$37.7M | -$39.3M | -$34.8M | -$31.8M | -$28.9M | — |
- Revenue +8% vs prior quarter ($31M vs $29M).
- Gross margin 56.5% (was 54.8% prior quarter).
- Operating margin expanded to -121.6%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue | $95.1M | $59.8M | $27.8M | $7.6M |
| Op margin | -141.6% | -177.8% | -305.8% | -1054.0% |
| Net income | -$132M | -$114M | -$94.1M | -$84.2M |
| Gross margin | 51.4% | 40.5% | 1.3% | -139.6% |
| Gross profit | $48.9M | $24.2M | $0.4M | -$10.7M |
| Operating income | -$135M | -$106M | -$85.1M | -$80.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
2026-09-22 · Kestra Medical Technologies (KMTS) Could Be 17% Undervalued Following Raised Revenue Outlook
2026-09-17 · Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?
2026-09-15 · KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 2027 Earnings Call Summary
2026-09-15 · Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60% as ...
2026-09-14 · Kestra Medical Technologies Q1 Earnings Call Highlights
2026-09-14 · Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
2026-09-14 · Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
2026-09-11 · AI Infrastructure Stock Forgent Power, Cardiovascular Play Kestra In Earnings Spotlight
2026-09-11 · Kestra Medical Technologies Ltd (KMTS) Q1 2027 Earnings Report Preview: What To Look For
2026-09-10 · Kestra Names Daniel Finney Vice President of Research & Development
2026-09-07 · Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for
Price (daily)
Full chart · RSI · MACD · patterns